Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 19;12:5049. doi: 10.1038/s41467-021-25175-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Waterfall plots of the response of eight research-ready PDXs to talazoparib combination therapies using the one animal per model per treatment (1 × 1 × 1) approach after up to 28 days of treatment. Data presented as the percent change in tumor volume compared to day 0 of treatment (%D0), with a good response shown in green (tumor volume regressed to <100% of starting volume), a partial response shown in yellow (tumor volume between 100–300% of starting volume and ≤50% volume of matched vehicle) and no response shown in orange (tumor volume >300% of starting volume), # tumor volume increases over 600% are not represented. (b) Graphs show tumor volume (%D0) for PDXs treated with vehicle (dotted line) or talazoparib (T) and carboplatin (C) combination therapy (solid line) for up to 28 days using the 1 × 1 × 1 approach (response—green; partial response—yellow; no response— orange). c–e Expansion of talazoparib and carboplatin combination therapy in five PDXs. Mice were treated for up to 28 days with vehicle (V; black; n = 6–8 grafts), 0.33 mg/kg talazoparib (T; dark blue; n = 6–8 grafts), 50 mg/kg carboplatin (C; light blue; n = 6–8 grafts) or talazoparib and carboplatin (T + C; pink; n = 6–8 grafts). Graphs show (c) tumor volume (%D0) for treatment groups (mean ± SEM; ^aP < 0.05 compared to vehicle, ^bP < 0.05 compared to talazoparib; linear mixed model analysis with a test of simple main effects, exact P values listed in Supplementary Data 8), d tumor volume (mm³) for individual animals; and, e fold change in tumor volume from day 0 to end of treatment (mean ± SEM; PDX 167.2M Cx—^aP = 0.0063 compared to vehicle, ^bP = 0.0181 compared to talazoparib; PDX 224R-Cx—^a,dP < 0.0001 compared to vehicle, ^bP = 0.0012 compared to vehicle, ^cP = 0.0047 compared to talazoparib and ^eP < 0.0001 compared to carboplatin; PDX 426M-Cx—^aP = 0.0196 compared to vehicle, ^bP = 0.0013 compared to vehicle and ^cP = 0.0358 compared to talazoparib; one-way ANOVA with post hoc Tukey’s test). Source data are provided as a Source Data file.